Polyrizon Ltd. (NASDAQ:PLRZ – Get Free Report) shares were down 2.2% on Thursday . The stock traded as low as $0.69 and last traded at $0.70. Approximately 172,131 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 2,946,580 shares. The stock had previously closed at $0.72.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised Polyrizon to a “sell” rating in a research report on Saturday, May 31st.
View Our Latest Stock Analysis on PLRZ
Polyrizon Price Performance
Institutional Investors Weigh In On Polyrizon
An institutional investor recently bought a new position in Polyrizon stock. Citadel Advisors LLC bought a new position in Polyrizon Ltd. (NASDAQ:PLRZ – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 38,337 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.91% of Polyrizon at the end of the most recent reporting period.
Polyrizon Company Profile
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Read More
- Five stocks we like better than Polyrizon
- Trading Stocks: RSI and Why it’s Useful
- Rigetti Computing: Cantor’s Bullish Call May Be Just the Start
- What Is WallStreetBets and What Stocks Are They Targeting?
- Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
- How to Use the MarketBeat Dividend Calculator
- 3 Top Stocks Under $20 Riding the “Made in America” Wave
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
